BGB-A317-305
Completed
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
BeOne Study ID
BGB-A317-305
ClinicalTrials.gov ID
EudraCT or EUCT Number
2018-000312-24
China Drug Trials ID
CTR20181841
Study Overview
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? No
Study Documents
Study Protocol Statistical Analysis Plan Plain Language SummaryStudy Overview
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? No